Back to Search
Start Over
Early Treatment with Human Albumin Solution in Continuous Renal Replacement Patients.
- Source :
-
Blood Purification . 2021, Vol. 50 Issue 2, p205-213. 9p. - Publication Year :
- 2021
-
Abstract
- Aims: To study the impact of early human albumin solution (HAS) in continuous renal replacement therapy (RRT) patients. Methods: Analysis of Randomized Evaluation of Normal versus Augmented Level (RENAL) RRT trial data. Results: Of 1,464 patients, 500 (34%) received early albumin. These patients had higher illness severity scores, greater use of mechanical ventilation, and 90-day mortality (51 vs. 41%; p < 0.001). However, early albumin carried similar RRT dependence risk among survivors at day 90 (4.9 vs. 5.8%; p = 0.62). On Cox proportional hazards regression, with standardized inverse probability of treatment weighting, early albumin was not associated with increased mortality (hazard ratio [HR]: 1.23, 95% CI: 0.97–1.55; p = 0.09) or recovery to RRT independence (HR: 0.92, 95% CI: 0.78–1.10; p = 0.38). Conclusions: Early albumin was administered to one-third of RENAL trial patients and in those with greater illness severity. Early albumin was not independently associated with mortality risk or rate of recovery to RRT independence. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 02535068
- Volume :
- 50
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- Blood Purification
- Publication Type :
- Academic Journal
- Accession number :
- 149043494
- Full Text :
- https://doi.org/10.1159/000509890